Thus, we believe that NCTD inhibit tumor growth and lymphangiogenesis of HCACs in vitro and in vivo by downregulating the VEGF-C,-D/VEGFR-3 signaling pathway and the VEGF-A/VEGFR-2 signaling pathway. This evidence concerns the gene KDR and neoplasm.